Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

BACKGROUND: Combination treatment with immune checkpoint inhibitors and antiangiogenic drugs has shown encouraging preliminary antitumor activity across various tumor types including advanced or metastatic renal cell carcinoma (aRCC). The open-label, parallel-cohort, dose-escalation, phase I CheckMa...

Descripción completa

Detalles Bibliográficos
Autores principales: Amin, Asim, Plimack, Elizabeth R, Ernstoff, Marc S, Lewis, Lionel D, Bauer, Todd M, McDermott, David F, Carducci, Michael, Kollmannsberger, Christian, Rini, Brian I, Heng, Daniel Y C, Knox, Jennifer, Voss, Martin H, Spratlin, Jennifer, Berghorn, Elmer, Yang, Lingfeng, Hammers, Hans J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196426/
https://www.ncbi.nlm.nih.gov/pubmed/30348216
http://dx.doi.org/10.1186/s40425-018-0420-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196426/
https://www.ncbi.nlm.nih.gov/pubmed/30348216
http://dx.doi.org/10.1186/s40425-018-0420-0

Ejemplares similares